<Anchor>

The stock market has been tumbling in recent years due to the overlapping bad news. The stock price of Sillagen, once known as the representative of KOSDAQ biotech companies, has fallen to a third of its share since Friday. With the controversy over the morality of employees, distrust in the entire bio industry is growing.

I am a reporter.

<Reporter>

Today's (Sir 7) shares closed at 1,200 won, down more than 7% from yesterday.

In the past four days, from today's two days, the stock has been a third.

Mr. Moon bought 2 billion won yesterday and 1.6 billion won today, but did not stop the decline.

The U.S. Data Monitoring Board's recommendation to stop phase III clinical trials of anticancer drugs for advanced liver cancer.

Shillagen says the recommendation is due to clinical procedure issues, and clinical trials for kidney cancer and colon cancer in addition to liver cancer are still ongoing.

However, morality controversy over the past year was reported when manager-level employees left 9.4 billion won in stock options, and an executive sold $ 8.8 billion in stock last month, before the US recommendation.

An independent lawmaker cited the possibility of financial fraud and insisted that an investigation is necessary.

Following the insurer scandal and the controversy over Sillagen, investor sentiment in the pharmaceutical and bio sectors contracted significantly.

Related companies have begun to evolve their anxiety by informing them of the clinical situation and future procedures.

[Kim, Hak-Kyun / Shinyoung Securities Research Center: Growth stocks such as BIO are buying a concept. I live to see the growth of the technology. I think that a lot of those beliefs have been damaged in recent events.]

The domestic bio industry is expected to announce the results of Phase III clinical trials of approximately four new drugs within this year.

It is true that domestic bio companies are making recent progress, but it is necessary to be cautious about investment considering the possibility of loss.

(Video coverage: Jung Kyung Moon, Video editing: Park Jin Hoon)